Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19091464 | NERVE GROWTH FACTOR AND METHODS OF USE THEREOF FOR NEURODEVELOPMENTAL DISABILITIES ASSOCIATED WITH NEONATAL HYPOXIC-ISCHEMIC ENCEPHALOPATHY | March 2025 | February 2026 | Allow | 11 | 2 | 0 | Yes | No |
| 18996523 | PROTEIN ANTIGEN COMBINATION FOR DETECTION OF ALZHEIMER'S DISEASE AND APPLICATION THEREOF | January 2025 | February 2026 | Allow | 13 | 2 | 0 | No | No |
| 18953476 | METHODS FOR PREVENTING AND TREATING BRAIN INFLAMMATION | November 2024 | November 2025 | Allow | 11 | 3 | 0 | Yes | No |
| 18763515 | DIAGNOSING MILD COGNITIVE IMPAIRMENT (MCI), PREDICTING ALZHEIMER'S DISEASE (AD) DEMENTIA ONSET, AND SCREENING AND MONITORING AGENTS FOR TREATING MCI OR PREVENTING DEMENTIA ONSET | July 2024 | December 2025 | Allow | 18 | 1 | 0 | Yes | No |
| 18735006 | METHODS AND COMPOSITIONS FOR DIAGNOSING BRAIN INJURY OR NEURODEGENERATION | June 2024 | October 2025 | Allow | 17 | 1 | 0 | Yes | No |
| 18646957 | GENE THERAPIES FOR LYSOSOMAL DISORDERS | April 2024 | September 2025 | Allow | 17 | 2 | 0 | Yes | No |
| 18640030 | NOVEL BIOMARKERS AND METHODS FOR DIAGNOSING AND EVALUATING TRAUMATIC BRAIN INJURY | April 2024 | August 2025 | Abandon | 16 | 1 | 0 | No | No |
| 18609247 | TREATMENT OF HEADACHE USING ANTI-CGRP ANTIBODIES | March 2024 | September 2024 | Allow | 6 | 1 | 0 | No | No |
| 18609223 | ACUTE TREATMENT AND RAPID TREATMENT OF HEADACHE USING ANTI-CGRP ANTIBODIES | March 2024 | September 2024 | Allow | 6 | 1 | 0 | No | No |
| 18607723 | METHODS OF TREATING PRADER-WILLI SYNDROME | March 2024 | August 2025 | Abandon | 17 | 1 | 0 | No | No |
| 18600801 | COMPOSITIONS AND METHODS FOR DISSOLVING PROTEIN AGGREGATES | March 2024 | June 2025 | Allow | 15 | 2 | 0 | No | No |
| 18596310 | ALPHA-SYNUCLEIN DETECTION USING BEADS | March 2024 | July 2025 | Allow | 16 | 2 | 0 | No | No |
| 18588150 | METHODS FOR AIDING IN DIAGNOSING AND EVALUATING A MILD TRAUMATIC BRAIN INJURY IN A HUMAN SUBJECT USING CARDIAC TROPONIN I AND EARLY BIOMARKERS | February 2024 | August 2025 | Abandon | 18 | 1 | 0 | No | No |
| 18417630 | COMPOSITIONS AND METHODS OF MUSCLE SPECIFIC KINASE CHIMERIC AUTOANTIBODY RECEPTOR CELLS | January 2024 | January 2026 | Allow | 24 | 2 | 0 | No | No |
| 18395097 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASES COMPRISING COX2 ACETYLATING AGENT AS ACTIVE INGREDIENT | December 2023 | June 2025 | Allow | 18 | 2 | 0 | No | No |
| 18529720 | DELTA-2-TUBULIN AS A BIOMARKER AND THERAPEUTIC TARGET FOR PERIPHERAL NEUROPATHY | December 2023 | March 2026 | Allow | 27 | 2 | 1 | No | No |
| 18513394 | SEPTAPEPTIDES ASSOCIATED WITH NEURODEGENERACY | November 2023 | July 2025 | Abandon | 20 | 0 | 1 | No | No |
| 18512323 | METHOD OF SCREENING COMPOUNDS FOR TREATING CNS DISORDERS | November 2023 | November 2025 | Abandon | 24 | 2 | 0 | No | No |
| 18509866 | DETECTION OF PATHOLOGICAL PROTEIN AGGREGATION | November 2023 | October 2025 | Allow | 23 | 2 | 0 | Yes | No |
| 18486417 | METHOD OF IDENTIFYING MALODOR MODULATING COMPOUNDS | October 2023 | November 2025 | Abandon | 25 | 1 | 1 | No | No |
| 18475838 | COMPOSITIONS AND METHODS FOR TREATING NON-HEMORRHAGIC CLOSED HEAD INJURY | September 2023 | August 2024 | Allow | 11 | 2 | 0 | No | No |
| 18306992 | ERYTHROCYTE-DERIVED EXTRACELLULAR VESICLES AND PROTEINS ASSOCIATED WITH SUCH VESICLES AS BIOMARKERS FOR PARKINSON'S DISEASE | September 2023 | May 2025 | Allow | 24 | 1 | 0 | No | No |
| 18460055 | METHODS OF TREATING PRADER WILLI SYNDROME AND CONDITIONS ASSOCIATED WITH LOW BASAL METABOLIC RATE OR HYPERPHAGIA USING A KATP CHANNEL OPENER | September 2023 | February 2026 | Allow | 30 | 3 | 0 | Yes | Yes |
| 18447290 | BLOOD BIOMARKER THAT PREDICTS PERSISTENT COGNITIVE DYSFUNCTION AFTER CONCUSSION | August 2023 | May 2025 | Allow | 22 | 2 | 0 | No | No |
| 18347108 | INNATE IMMUNE PROTEINS AS BIOMARKERS FOR CNS INJURY | July 2023 | October 2025 | Allow | 28 | 2 | 1 | No | No |
| 18206133 | METHODS OF DIAGNOSING ALZHEIMER'S DISEASE AND RISK OF PROGRESSION TO ALZHEIMER'S DISEASE | June 2023 | September 2025 | Allow | 28 | 2 | 0 | No | No |
| 18327243 | METHOD OF TREATING LARGE VESSEL OCCLUSION STROKE | June 2023 | December 2025 | Allow | 30 | 2 | 0 | No | No |
| 18195170 | Methods of Identifying Schizophrenia Patients At Risk for Relapse | May 2023 | August 2025 | Abandon | 27 | 2 | 0 | No | No |
| 18313792 | METHODS OF TREATING AL AMYLOIDOSIS | May 2023 | January 2025 | Allow | 20 | 1 | 0 | No | No |
| 18310381 | SEROLOGIC ASSAY FOR SILENT BRAIN ISCHEMIA | May 2023 | November 2025 | Abandon | 30 | 2 | 1 | Yes | No |
| 18300535 | p53 Peptides as Markers in the Diagnosis and Prognosis of Alzheimer's Disease | April 2023 | February 2025 | Abandon | 22 | 0 | 1 | No | No |
| 18298953 | ANTIBODY-PEPTIDE FUSION PROTEINS FOR TREATING AMYLOID DISORDERS | April 2023 | September 2024 | Allow | 17 | 2 | 1 | No | No |
| 18297883 | METHODS FOR DIAGNOSING HUNTINGTON’S DISEASE | April 2023 | April 2025 | Allow | 24 | 2 | 0 | No | No |
| 18182822 | TREATMENT OF MOST BOTHERSOME SYMPTOM (MBS) ASSOCIATED WITH MIGRAINE USING ANTI-CGRP ANTIBODIES | March 2023 | March 2025 | Allow | 24 | 2 | 0 | No | No |
| 18173116 | ACUTE TREATMENT AND RAPID TREATMENT OF HEADACHE USING ANTI-CGRP ANTIBODIES | February 2023 | March 2025 | Allow | 24 | 1 | 0 | Yes | No |
| 18173124 | TREATMENT OF HEADACHE USING ANTI-CGRP ANTIBODIES | February 2023 | March 2025 | Allow | 24 | 1 | 0 | Yes | No |
| 18111172 | TREATING REFRACTORY MIGRAINE | February 2023 | July 2024 | Allow | 17 | 2 | 0 | No | No |
| 18102852 | BIOMARKERS AND METHODS FOR DETECTION OF SEIZURES AND EPILEPSY | January 2023 | June 2025 | Abandon | 28 | 2 | 0 | No | No |
| 18095660 | HEXOKINASE 2-SPECIFIC INHIBITORS FOR USE IN ACUTE CENTRAL NERVOUS SYSTEM INJURY | January 2023 | January 2025 | Allow | 25 | 2 | 0 | No | No |
| 18150377 | OPTIMIZED MINI-DYSTROPHIN GENES AND EXPRESSION CASSETTES AND THEIR USE | January 2023 | November 2024 | Allow | 22 | 1 | 0 | No | No |
| 18069838 | ANTI-TRANSFERRIN RECEPTOR ANTIBODIES WITH TAILORED AFFINITY | December 2022 | November 2024 | Allow | 23 | 1 | 0 | No | No |
| 17924622 | GLUTATHIONE TRISULFIDE (GSSSG) IN NEUROPROTECTION | November 2022 | December 2025 | Allow | 37 | 1 | 0 | No | No |
| 17982769 | MULTI-PROTEIN BIOMARKER ASSAY FOR BRAIN INJURY DETECTION AND OUTCOME | November 2022 | February 2025 | Allow | 28 | 1 | 1 | No | No |
| 17971081 | IMMOBILIZED PROTEIN SYSTEM FOR RAPID AND ENHANCED MULTIPLEXED DIAGNOSTICS | October 2022 | February 2025 | Abandon | 28 | 0 | 1 | No | No |
| 17937339 | PATHOLOGIC TDP-43 AS A BIOMARKER FOR THE DIAGNOSIS OF TDP-43 PROTEINOPATHY | September 2022 | March 2026 | Allow | 42 | 2 | 1 | Yes | No |
| 17912776 | RET (REARRANGED DURING TRANSFECTION) FOR THE ASSESSMENT OF STROKE | September 2022 | February 2026 | Abandon | 41 | 1 | 0 | No | No |
| 17876923 | LACTOFERRIN FOR USE IN THE DIAGNOSIS OR PROGNOSIS OF ALZHEIMER'S DISEASE, OR IN THE DIAGNOSIS OF PARKINSON'S DISEASE | July 2022 | January 2025 | Abandon | 30 | 0 | 1 | No | No |
| 17814486 | BLOOD-BASED DIAGNOSTIC ASSAYS FOR ALZHEIMER'S DISEASE | July 2022 | January 2026 | Abandon | 42 | 0 | 1 | No | No |
| 17791625 | NPTN65 IS A NEW TARGET FOR THE TREATMENT OF TAUOPATHIES | July 2022 | December 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17788445 | Predictive Markers of Psychosis | June 2022 | January 2026 | Abandon | 42 | 0 | 1 | No | No |
| 17757939 | METHOD FOR COLLECTING EXTRACELLULAR VESICLES DERIVED FROM NERVOUS SYSTEM CELLS | June 2022 | February 2026 | Allow | 44 | 2 | 1 | Yes | No |
| 17845021 | INHIBITION OF AUTISM SPECTRUM DISORDER USING DECOY ANTIGENS TO MATERNAL BRAIN-REACTIVE ANTIBODIES | June 2022 | April 2025 | Allow | 34 | 2 | 1 | No | No |
| 17839669 | METHODS OF DIAGNOSING OR AIDING IN DIAGNOSIS OF BRAIN INJURY CAUSED BY ACOUSTIC ENERGY, ELECTROMAGNETIC ENERGY, AN OVER PRESSURIZATION WAVE, AND/OR BLAST WIND | June 2022 | March 2026 | Abandon | 45 | 1 | 1 | No | No |
| 17836475 | COMPOSITIONS FOR RESTORING GENE EXPRESSION IN NEUROPSYCHIATRIC OR NEURODEGENERATIVE DISORDERS | June 2022 | March 2026 | Allow | 45 | 4 | 0 | Yes | No |
| 17831619 | MUTANT PROTEINS AND METHODS FOR THEIR PRODUCTION | June 2022 | May 2025 | Abandon | 35 | 1 | 1 | No | No |
| 17827933 | BIOMARKER FOR ALZHEIMER'S DISEASE | May 2022 | December 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17751704 | Memory in subjects with mini-mental state examination of 24-26 | May 2022 | December 2024 | Allow | 31 | 2 | 1 | Yes | No |
| 17776391 | GAMMA-SECRETASE STABILIZING COMPOUND SCREENING ASSAY | May 2022 | December 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17734821 | METHODS AND COMPOSITIONS FOR THE IMPROVEMENT OF LYSOSOMAL FUNCTION AND TREATMENT OF NEURODEGENERATIVE DISEASE | May 2022 | January 2025 | Abandon | 33 | 0 | 1 | No | No |
| 17731185 | METHODS FOR THE PREDICTION, PROGNOSIS, AND/OR DIAGNOSIS OF AN INFLAMMATORY RESPONSE ASSOCIATED WITH SCHIZOPHRENIA | April 2022 | January 2026 | Allow | 44 | 1 | 0 | Yes | No |
| 17726367 | ANTI-TREM2 ANTIBODIES AND METHODS OF USE THEREOF | April 2022 | January 2026 | Abandon | 45 | 3 | 1 | No | No |
| 17724168 | Alpha-Synuclein mutants and uses thereof | April 2022 | January 2026 | Allow | 45 | 2 | 1 | No | No |
| 17718789 | PEPTIDE | April 2022 | January 2025 | Allow | 33 | 1 | 0 | No | No |
| 17637700 | ASSAYS FOR DETECTING AND QUANTIFYING A BIOMARKER OF PERICYTE INJURY | February 2022 | December 2025 | Abandon | 45 | 1 | 1 | No | No |
| 17649760 | SCREENING METHOD | February 2022 | December 2024 | Abandon | 34 | 1 | 0 | No | No |
| 17647289 | ASTROCYTE TRAUMATOME AND NEUROTRAUMA BIOMARKERS | January 2022 | February 2025 | Allow | 37 | 2 | 0 | No | No |
| 17569251 | SCREENING METHODS USING CANINE T2R RECEPTORS AND PET FOOD PRODUCTS AND COMPOSITIONS IDENTIFIED USING THE SAME | January 2022 | January 2026 | Allow | 49 | 4 | 1 | Yes | No |
| 17560297 | MARKERS AND THEIR USE IN BRAIN INJURY | December 2021 | July 2025 | Allow | 42 | 2 | 0 | No | No |
| 17556584 | METHODS FOR REDUCING POST-OPERATIVE COGNITIVE DYSFUNCTION (POCD) | December 2021 | February 2025 | Allow | 38 | 2 | 0 | No | No |
| 17621189 | ANTI-CGRP RECEPTOR/ANTI-PAC1 RECEPTOR BISPECIFIC ANTIGEN BINDING PROTEINS | December 2021 | March 2026 | Allow | 50 | 2 | 1 | Yes | No |
| 17553173 | METHODS FOR DIAGNOSING ALZHEIMER'S DISEASE AND OTHER NEUROLOGICAL DISORDERS | December 2021 | July 2025 | Allow | 43 | 2 | 1 | No | No |
| 17617504 | APOLIPOPROTEIN E FRAGMENTS | December 2021 | October 2025 | Abandon | 46 | 0 | 1 | No | No |
| 17610016 | METHODS AND COMPOSITIONS FOR INHIBITING ADAM8 BIOLOGICAL ACTIVITIES | November 2021 | September 2025 | Abandon | 46 | 1 | 0 | No | No |
| 17609995 | EVALUATING BIOMARKERS ALONG WITH ADVANCED MAGNETIC RESONANCE IMAGING PROCEDURES IN A HUMAN SUBJECT THAT HAS SUSTAINED OR MAY HAVE SUSTAINED A HEAD INJURY | November 2021 | August 2025 | Abandon | 46 | 1 | 2 | No | No |
| 17608220 | TREATMENT OF HEADACHE USING ANTI-CGRP ANTIBODIESHEREOF | November 2021 | December 2025 | Allow | 49 | 2 | 0 | No | No |
| 17606982 | ALPHA-SYNUCLEIN ASSAYS | October 2021 | November 2025 | Abandon | 48 | 1 | 1 | Yes | No |
| 17594614 | CATECHOLAMINE CONCENTRATIONS IN A BLOOD SAMPLE AND ARTERIAL HYPERTENSION STATUS IN A SUBJECT FOR A DIFFERENTIAL DIAGNOSIS OF NEURODEGENERATIVE DISEASES INCLUDING ALZHEIMER'S DISEASE | October 2021 | August 2025 | Abandon | 46 | 1 | 0 | No | No |
| 17594648 | PCSK9 INHIBITORS FOR NEUROPATHY | October 2021 | August 2025 | Abandon | 46 | 0 | 1 | No | No |
| 17497776 | CIRCULATING BIOMARKER LEVELS FOR DIAGNOSIS AND RISK-STRATIFICATION OF TRAUMATIC BRAIN INJURY | October 2021 | November 2024 | Allow | 38 | 2 | 0 | No | No |
| 17485850 | Compositions and Methods for Uncoupling TrkB Receptor from PLC Gamma 1 for the Treatment of Epilepsy and Anxiety-Like Disorder | September 2021 | November 2024 | Abandon | 38 | 1 | 1 | No | No |
| 17483047 | GPR156 Variants And Uses Thereof | September 2021 | October 2024 | Allow | 37 | 2 | 1 | No | No |
| 17483517 | CD14 ANTAGONIST ANTIBODIES FOR TREATING NEURODEGENERATIVE DISEASES | September 2021 | January 2025 | Allow | 40 | 2 | 0 | No | No |
| 17477687 | ANTI-TAUC3 ANTIBODIES AND USES THEREOF | September 2021 | July 2024 | Allow | 34 | 1 | 0 | No | No |
| 17411511 | METHODS FOR AIDING IN DIAGNOSING AND EVALUATING A MILD TRAUMATIC BRAIN INJURY IN A HUMAN SUBJECT USING CARDIAC TROPONIN I | August 2021 | August 2024 | Allow | 36 | 2 | 0 | Yes | No |
| 17378401 | ANTIGENIC PEPTIDES AND USES THEREOF FOR DIAGNOSING AND TREATING AUTISM | July 2021 | January 2026 | Allow | 54 | 5 | 0 | Yes | No |
| 17366991 | ErbB2 SIGNALING AND NERVE REGENERATION | July 2021 | October 2024 | Allow | 40 | 2 | 0 | No | No |
| 17346152 | METHODS AND SYSTEMS FOR IDENTIFYING MODULATORS OF PERVASIVE DEVELOPMENTAL DISORDERS | June 2021 | April 2025 | Abandon | 46 | 3 | 0 | No | No |
| 17312445 | Cell Body Targeted Sensors | June 2021 | February 2025 | Allow | 45 | 1 | 1 | No | No |
| 17316230 | METHODS FOR AIDING IN THE DIAGNOSIS AND DETERMINATION OF THE EXTENT OF TRAUMATIC BRAIN INJURY IN A HUMAN SUBJECT USING THE EARLY BIOMARKER UBIQUITIN CARBOXY-TERMINAL HYDROLASE L1 | May 2021 | April 2024 | Allow | 35 | 2 | 0 | Yes | No |
| 17237314 | TEST METHOD FOR OLFACTORY MUCOSA OR OLFACTORY MUCUS IN MAMMALS | April 2021 | November 2025 | Abandon | 55 | 4 | 0 | No | No |
| 17284220 | SCREENING METHOD FOR THERAPEUTIC DRUG OR PROPHYLACTIC DRUG FOR TAUOPATHY AND DIAGNOSTIC METHOD FOR TAUOPATHY | April 2021 | January 2025 | Abandon | 45 | 1 | 1 | No | No |
| 17154966 | DISCRIMINATING PARKINSON'S DISEASE FROM MULTIPLE SYSTEM ATROPHY USING ALPHA-SYNUCLEIN PMCA | January 2021 | December 2024 | Allow | 46 | 3 | 0 | Yes | No |
| 16973502 | MATERIALS AND METHODS FOR TREATING STRESS-RELATED DISORDERS AND CANCER | December 2020 | November 2024 | Allow | 47 | 1 | 1 | No | No |
| 17085677 | Treatment of Neurodegenerative Conditions by Disruption of Rhes | October 2020 | September 2025 | Allow | 59 | 6 | 0 | Yes | No |
| 17046648 | BRAIN NATRIURETIC PEPTIDE ENGRAFTED ANTIBODIES | October 2020 | April 2025 | Allow | 54 | 2 | 1 | No | No |
| 16978022 | ANTI-PHF-TAU ANTIBODIES AND USES THEREOF | September 2020 | October 2024 | Allow | 50 | 3 | 0 | No | No |
| 16969835 | TAU SINGLE DOMAIN ANTIBODIES | August 2020 | August 2024 | Allow | 48 | 4 | 0 | Yes | No |
| 16968812 | Pulse Stable Tracer Methods for Detection of Short-Chain Fatty Acids | August 2020 | July 2025 | Allow | 59 | 3 | 0 | No | No |
| 16651926 | METHODS FOR IDENTIFYING AND TREATING ADRENOMYELONEUROPATHY (AMN) | March 2020 | December 2024 | Allow | 57 | 2 | 2 | No | No |
| 16673767 | CHANNEL MODULATORS | November 2019 | November 2024 | Abandon | 60 | 4 | 1 | No | Yes |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner CHERNYSHEV, OLGA N.
With a 71.4% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 43.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner CHERNYSHEV, OLGA N works in Art Unit 1675 and has examined 226 patent applications in our dataset. With an allowance rate of 92.0%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 38 months.
Examiner CHERNYSHEV, OLGA N's allowance rate of 92.0% places them in the 78% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.
On average, applications examined by CHERNYSHEV, OLGA N receive 2.71 office actions before reaching final disposition. This places the examiner in the 80% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by CHERNYSHEV, OLGA N is 38 months. This places the examiner in the 29% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +5.6% benefit to allowance rate for applications examined by CHERNYSHEV, OLGA N. This interview benefit is in the 32% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.
When applicants file an RCE with this examiner, 24.8% of applications are subsequently allowed. This success rate is in the 37% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 49.4% of cases where such amendments are filed. This entry rate is in the 74% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 100.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 70% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 82.1% of appeals filed. This is in the 75% percentile among all examiners. Of these withdrawals, 62.5% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 77.8% are granted (fully or in part). This grant rate is in the 83% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 20.4% of allowed cases (in the 98% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 3.8% of allowed cases (in the 77% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.